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Encapsulating peritoneal sclerosis (EPS) is a serious condition
whose frequency is increasing the longer the duration of
peritoneal dialysis. To identify prognostic indicators of EPS,
we studied here longitudinal changes in peritoneal
membrane function of patients who later developed this
complication. We identified all patients with an unequivocal
diagnosis of EPS who began their peritoneal dialysis in our
unit over a 20-year period and matched each of them for
dialysis duration and age with four control patients who
completed their dialysis. The dialysate/plasma creatinine
ratio increased with time in both groups but was significantly
higher in the patients with EPS only at the time their dialysis
was discontinued. The ultrafiltration capacity was
significantly worse for at least 2 years before stopping
dialysis, diverging further at the time dialysis ceased,
suggesting reduced osmotic conductance in the EPS patients.
Both the glucose exposure rate for the 5 years preceding
stoppage of dialysis and exposure to the osmotic agent
icodextrin were significantly higher. Residual renal function
was less in the EPS group, but there was no significant
difference in the rates of peritonitis compared to the control
group. The 24h peritoneal protein clearance was not
significantly different in EPS patients, possibly due to
a greater fibrous matrix. Thus, our study shows that regular
peritoneal membrane function tests can identify most
patients at high risk of developing EPS before its occurrence.
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Encapsulating peritoneal sclerosis (EPS) is an increasingly
recognized complication of peritoneal dialysis (PD), char-
acterized by development of a diffuse ‘cocoon’ over the small
bowel causing gastrointestinal symptoms and bowel obstruc-
tion, leading to weight loss, undernutrition and in some cases
death. The incidence increases with time on PD, ranging
from 0% during the first 3 years to 5.9% for patients on PD
between 8 and 10 years in Japan,1 and from 0% during the
first year to 8% for patients on PD for 5 or more years in
Scotland.2 Several treatment-related risk factors have been
suggested including severe peritonitis, glucose exposure, lack
of residual renal function and the development of ultrafiltra-
tion (UF) failure associated with high rates of membrane
solute transport. Paradoxically, discontinuation of PD
appears to be a trigger factor for developing the condition
resulting in a therapeutic dilemma for the clinician as to
when and if patients should be switched to hemodialysis.
Although EPS is rarely seen in patients not exposed to PD,
other precipitants such as cirrhosis with ascites, postsurgical,
peritoneal shunts, autoimmune conditions and intraperito-
neal chemotherapy3,4 are described and the underlying
pathophysiology remains obscure. This is compounded by
the lack of a good animal model, the rarity of the disease and
the lack of stringent diagnostic criteria.
The ability to identify patients at high risk, thereby
prompting consideration of switching to hemodialysis or
transplantation, might be facilitated by identifying changes in
peritoneal membrane function that precede or predispose to
the development of EPS. It is well established that time on PD
is associated with increases in peritoneal solute transport rate
(PSTR) associated with a decrease in the UF capacity of the
membrane. In a proportion of patients, there is uncoupling
of these two processes due to a decrease in the osmotic
conductance of the membrane that may well reflect the
progressive fibrosis associated with longer time on treatment.
These changes in membrane function are associated with
more rapid loss in residual renal function and higher glucose
exposure, which may contribute to further fibrosis and
subsequent EPS. To date, most studies of EPS patients have
reported only the results of the most recent peritoneal
membrane function tests before diagnosis. We report the first
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controlled longitudinal cohort study of peritoneal membrane
function with associated detailed clinical measurement
including residual renal function and peritoneal glucose
exposure in patients who subsequently develop definite EPS.
RESULTS
Nine patients with definite EPS were identified from a total
cohort of 692 patients treated with PD since 1990. The
diagnosis of EPS was confirmed surgically in five out of nine
patients, and radiologically in seven out of nine (Table 1).
Three patients were on PD at the time of diagnosis, whereas
the other six were on hemodialysis, a mean of 7.3 months
after stopping PD (range 1–18 months). Constipation was
unusual, whereas diarrhea occurred in only three out of nine.
Frank obstruction was only diagnosed formally in four out of
nine, although vomiting occurred in six out of nine.
EPS free survival is shown in Figure 1. The two early cases
of EPS (6 and 23 months) were both related to severe,
prolonged peritonitis episodes. Of the EPS not associated
with severe and prolonged peritonitis, there were no early
cases, with the first case occurring at 32 months. The risk rose
substantially after 5 years such that the probability of EPS free
survival after 93 months on PD was 0.85. The confidence
intervals for this are wide with small numbers of patients at
risk but they follow a pattern of an increasing gradient with
time in the Kaplan–Meier plot.
The demographics of the cases and 36 matched controls
are shown in Table 2 with no significant difference between
the groups. One EPS case had two significant sessions of PD
that, although separated by a 9-year period, were combined
into one for the analysis. The cohorts were reasonably
matched in time with a median date of stopping PD of 26
March 2004 in EPS cases and 9 April 2002 in the controls.
Predictably, the outcome of the two groups was significantly
different.
The mean number of peritonitis episodes was greater in
the control group, although this did not reach statistical
significance (1.78 vs 4.19, P¼ 0.061). Two EPS cases had no
peritonitis at all, only one had the catheter temporarily
removed for peritonitis and only two had peritonitis within
the 6 months before stopping PD.
Both EPS and control groups showed a gradual rise in
solute transport rate with time on treatment (P¼ 0.003 and
0.001, respectively) (Figure 2). The change of UF capacity
with time was significant (P¼ 0.02) in the EPS group
(Figure 3) but not in the control group (P¼ 0.34). Only two
of the control group of patients had a consistently low UF
capacity suggestive of UF failure.
For the same dialysate/plasma creatinine ratio (D/P Cr) in
both EPS and control groups, when D/P Cr and UF capacity
are plotted together (Figure 4), the decline in UF capacity
with increasing D/P Cr is disproportionately worse for the
EPS group such that there is a statistically significant
difference in UF (345 ml at 0.781 for control group vs
194 ml at 0.784 for EPS group, P¼ 0.015).
Five EPS cases had been on automated peritoneal dialysis
(APD), giving a mean duration on APD usage of 20.2 months
within EPS cases, and 19 controls had been on APD, giving a
mean duration of 13.1 months within controls. This
difference was not significant (P¼ 0.35). The mean annual
glucose exposure rates (Figure 5) were not statistically
significantly different for the last three readings due to an
increase in variance but the mean values still showed a clear
difference. The last year’s glucose exposures were 66,494 and
96,241 g per year in control and EPS groups, respectively;
four 2 l 1.36% or 2.27% exchanges per day correspond to a
yearly glucose exposure of 39,712 or 66,284 g per year,
respectively. Icodextrin use was greater in the EPS cases, but
the difference was only significant for between 1 and 2 years
before stopping PD (7/9 vs 12/36, P¼ 0.016).
Table 1 | Clinical features of patients with EPS
EPS
case
Age at
diagnosis Gender
Cumulative
months
on PD
Diagnosis
days
after PD
Days
survival
after
diagnosis
Cause of
death
Reason
for
stopping
PD
Abdominal
pain Ascites Vomiting
Weight
loss
Radiologically
confirmed
Surgically
confirmed
Surgical
treatment
Tamoxifen
treatment
Steroid
treatment
1 45.8 F 161 0 7 Multiorgan
failure
postoperatively
EPS Y Y Y N Y Y Y N N
2 34.6 F 130 0 33 Multiorgan
failure
Peritonitis Y Y Y Y N Y N N N
3 39.5 M 93 36 4729 Alive EPS Y Y Y Y Y Y Y Y Y
4 71.5 M 65 0 2 Bowel
obstruction
EPS/died Y N Y N Y N N N N
5 54.7 M 69 101 2 Sudden
death after
vomiting++
UF failure Y Y Y Y N Y N N N
6 65.6 M 65 560 120 Malnutrition,
withdrawal
of HD
Drainage
problems
Y Y Y Y Y N N Y N
7 44.3 F 55 320 221 Sudden
cardiac
death
UF failure N Y N Y Y N N Y N
8 26.8 F 93 47 4344 Alive UF failure Y Y Y Y Y Y Y N Y
9 60.0 M 32 296 48 Malnutrition Patient
choice
Y Y Y Y Y N N Y Y
Abbreviations: EPS, encapsulating peritoneal sclerosis; PD, peritoneal dialysis; UF, ultrafiltration; ++, severe and prolonged vomiting in this case.
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Over the first 4 years of PD, residual renal function was
significantly better preserved in controls with a mean urine
volume for EPS 339.6 ml vs controls 572 ml, P¼ 0.001
(Figure 6). Peritoneal protein clearances (PCl) were not
significantly lower in the EPS cases than the controls by
independent samples t-test (Figure 7). The EPS group did
have a lower PCl than controls in a linear mixed model with
EPS/controls and time to PD finish as predictor variables
using fixed effects but the model improved and the difference
became insignificant when a random effect was added for
EPS/controls or intercept. Although there were insufficient
samples to make meaningful comparisons on a time matched
basis, there was no significant longitudinal change from the
last year of PD to between 3 and 4 years before stopping PD
(94.50 vs 84.99 ml plasma per day, P¼ 0.46).
DISCUSSION
This is the first controlled analysis describing the longitudinal
changes of a number of treatment-related measures of PD
patients developing EPS. The characteristics of patients
destined to develop EPS were early loss of residual renal
function, and increased glucose exposure associated with
reduced UF capacity of the peritoneal membrane. In contrast,
baseline characteristics such as age, gender and comorbidity
or subsequent frequency of peritonitis were not different.
These observations have important implications for the
longitudinal monitoring, prevention and risk assessment of
patients on long-term PD.
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Figure 1 |Kaplan–Meier plot of encapsulating peritoneal sclerosis (EPS) free survival. The probability of remaining free of EPS with
duration of time on peritoneal dialysis (PD). This includes two early cases associated with severe, prolonged peritonitis. The number of
patients at risk at the time of each case of EPS is shown at the top.
Table 2 | Demographics of EPS cases and controls
EPS
(9 patients)
Controls
(36 patients) P-value
Duration of PD in months
(months; mean)
84.7 81.0 0.27
Age at PD cessation
(years; mean)
48.8 54.7 0.32
Male (%) 55.6 50 0.77
Ethnicity
White European (%) 88.9 97.2 0.28
South Asian (%) 11.1 2.8
Stoke comorbidity index (mean) 0.78 0.78 0.98
Low (%) 55.6 50.0 0.76
Intermediate (%) 44.4 44.4
High (%) 0 5.6
Diabetic (%) 0 16.7 0.19
Adequacy at treatment start
Renal Kt/V (median) 0.19 0.98 0.24
Renal Cr clearance (median) 9.86 48.4 0.27
Peritoneal Kt/V (mean) 1.60 1.60 0.61
PET at treatment start
D/P Cr (mean) 0.71 0.66 0.18
UF capacity (mean) 402 423 0.82
Modality immediately after PD
Hemodialysis (%) 88.9 30.6
Transplant (%) 0 33.3
Died (%) 11.1 36.1
Abbreviations: D/P Cr, dialysate/plasma creatinine ratio; EPS, encapsulating
peritoneal sclerosis; PD, peritoneal dialysis; UF, ultrafiltration.
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A higher risk of EPS has consistently been associated with
a longer duration of PD.1,5 The incidence in this study is in
line with this, with a lifetime risk of 8.75% for patients on PD
for more than 5 years, a finding in keeping with the incidence
reported by the Scottish Renal Registry.2 One of the strengths
of this study is follow-up data over a long period of time
(19 years) allowing us to examine EPS risk after long periods
on PD, and the Kaplan–Meier gradient continues to worsen
with longer PD exposure, a similar pattern to that published
by Kawaguchi et al.6 although in our center the decline in
EPS free survival is shorter.
It has been suggested that transplantation is a particular
risk for the development of EPS,7,8 although this does not
seem to be the case for our cohort (12 out of 36 controls vs 0
out of 9 EPS cases had a transplant) nor was it the case in the
Pan-Thames EPS study where 14 out of 65 patients had a
transplant.9 The majority of our patients developed the
condition after stopping PD (six out of nine) suggesting that,
as has been documented previously,1,10 cessation of PD may
be the main trigger.
The original reports of EPS linked it with an increased rate
and/or severity of peritonitis,5,11–13 although this is not the
case in our study. This might be explained by case selection
as, to ensure there was uniformity in the diagnosis of EPS, we
excluded two cases characterized by an early diagnosis after
severe and prolonged peritonitis. However, there have also
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Figure 2 |Change in membrane solute transport with time on
peritoneal dialysis (PD). Solute transport is measured as the
mean annual dialysate/plasma (D/P) creatinine ratio measured at
4 h in standard peritoneal equilibration tests with standard error.
The star indicates a difference between groups with P¼ 0.007.
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Figure 3 |Change in ultrafiltration capacity with time on
peritoneal dialysis (PD). The ultrafiltration (UF) capacity is the
annual mean measured by a 4 h peritoneal equilibration test with
2.27% glucose, including approximately 200ml overfill. Bars
represent standard error. The stars indicate a difference between
groups with Po0.05, unpaired t-test.
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Figure 4 |Change in membrane solute transport with change
in ultrafiltration. Membrane solute transport and ultrafiltration
(UF) are measured as the annual mean of measurements of UF
capacity and dialysate/plasma (D/P) creatinine ratio in a 4 h
peritoneal equilibration test with 2.27% glucose, including
approximately 200ml overfill. Bars represent standard error.
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Figure 5 |Glucose exposure with time on peritoneal dialysis
(PD). Glucose exposure is measured as the mean of the total
number of grams of glucose in the dialysate used by each patient
in that year. Bars represent standard error. The stars indicate a
difference between groups with Po0.05, unpaired t-test.
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been other recent case series where the rate of peritonitis was
unremarkable such as that from Kawanishi et al.,10 where 16
of 50 cases of EPS had no peritonitis, and Summers et al.14
and Hendriks et al.,15 where the rate of peritonitis was no
different to the entire PD population and control group,
respectively. These case series suggest infectious peritonitis is
no longer such an important feature. Changes in PSTR and
UF capacity have been documented with peritonitis,
particularly multiple and severe episodes,16 so there may be
a subset of patients in whom severe, nonresolving or
recurrent peritonitis is still important in the development
of EPS17 such as the two patients we excluded from this
analysis.
The PSTR might reflect intraperitoneal inflammation
through its association with local IL-6 levels18 and previous
studies have shown a faster PSTR in most patients who
develop EPS.15,19,20 This association with EPS is usually
reported in the context of a single measurement at differing
time points on dialysis so how this was related to the
evolution of EPS was unclear until now. Our study confirms
previous observations that PSTR tends to increase with time
on treatment and shows this was not obviously different
between EPS patients and controls, with the exception of the
last measurements taken within a year of diagnosis. This is in
keeping with previous observations, suggesting that the early
stages of EPS are inflammatory in nature with evidence of
local inflammatory changes in biopsies compared with
samples taken from patients with simple peritoneal sclerosis.21
Although a previous uncontrolled study failed to show an
increase in PSTR measured in four standardized permeability
analyses before the development of peritoneal sclerosis, our
controlled study of EPS included measurements from within
the final year of PD, the only time point at which there was a
significant difference in PSTR.22 The only previous report of
peritoneal protein loss (albumin and IgG) in EPS was in four
patients with no control group,19 where three had an increase
over time and one a decrease. By using a case–control design
with more cases, we have shown that EPS patients actually
have a slightly reduced PCl than time-matched controls.
UF failure at the time of PD cessation has been
documented as a risk factor for the development of
EPS,15,23 including the same uncontrolled longitudinal study
of peritoneal sclerosis mentioned above that showed a decline
in UF capacity over 4 years.22 This EPS study extends these
findings in time and by using time-matched controls, a clear
difference is apparent at least 2 years before PD cessation.
Our study has also shown for the first time uncoupling of
PSTR and UF capacity, with less UF capacity for the same
PSTR, in patients who subsequently develop EPS,24 also a
recognized phenomenon in long-term PD patients
without EPS.24 A possible explanation for this decrease in
osmotic conductance is increased fibrosis reducing hydraulic
permeability.
Glucose exposure has previously been documented as
higher in a group of peritoneal sclerosis patients compared
with controls,15 but this study again extends this to a
longitudinal description finding a clear separation between
cases and controls 4 years before stopping PD. Glucose
exposure might be a reflection of more use of APD, but in
our study cases and controls had similar rates of APD.
Unsurprisingly, icodextrin use was also more in EPS cases
given its known benefits in maintaining PD in patients with
UF failure, although this was only significant between 1 and 2
years before PD cessation. That glucose exposure is
statistically significantly different before the divergence in
the UF capacity does not necessarily imply that it precedes
the deterioration in UF capacity, as there is a small difference
in UF capacity at 4 years before PD cessation that is almost
significantly different (P¼ 0.07) and UF capacity in the
peritoneal equilibration test is recognized as having a large
coefficient of variation, limiting the ability to detect true
differences. The pattern of glucose exposure and UF capacity
is strikingly similar with the plots in both graphs diverging
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Figure 6 |Residual renal function with time on peritoneal
dialysis (PD). The residual renal function is measured as the
median of the urine volume within each group assessed every
6 months from the start of PD.
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Figure 7 |Peritoneal protein clearance with time on peritoneal
dialysis (PD). Peritoneal protein clearance is measured in ml of
plasma per day and the bars represent standard errors. There
were no significant differences between the groups when
applying mixed linear modeling.
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between 4 and 5 years before stopping PD and separating
further with time.
The longitudinal evolution of residual renal function has
not been studied previously, but this study showed that those
patients who go on to develop EPS pass a smaller urinary
volume within the first 4 years. This is likely to be another
contributory factor, along with declining UF capacity, in
explaining the EPS patients’ earlier and greater duration of
glucose exposure.
The ISPD position paper on PD duration25 emphasized
the desirability of a method of identifying those patients at
risk of EPS, not fulfilled by CT scanning,26 and there is as yet
no study on the use of biomarkers in predicting EPS. Patients
who lose their residual renal function quickly and have a
declining UF capacity, particularly a low UF capacity relative
to their PSTR, are the group at highest risk of EPS, and
consideration must be given to changing dialysis modality
although other important factors must also be considered
when discussing this.25 The glucose exposure may be a more
reliable marker than UF capacity as the glucose requirements
are likely to be set by the osmotic conductance to glucose of
the peritoneal membrane, whereas the measured UF capacity
is affected by other issues (e.g., catheter position and
drainage) and is thus more variable. This study has partially
overcome this issue by using the mean value of twice yearly
peritoneal membrane function tests.
From previous studies, the PSTR appeared to be an
independent predictor of EPS that could be monitored for
the purpose of identifying patients at risk. Our data suggest
that it would be of less use than glucose exposure or UF
capacity as clear separation between EPS cases and controls
only appeared in the last year of PD, by which point stopping
PD may well be too late, although a rapid increase in PSTR
could help identify patients who are already at high risk of
EPS at the point of modality switch and therefore require
close follow-up afterward.
Conventional glucose-based PD fluid contains glucose
degradation products, is acidic, and, particularly for 3.86%
bags, possesses an unphysiologically high osmolality, all of
which are thought to contribute to membrane damage with
an increase in PSTR in conjunction with a worse residual
renal function.27 This study has provided a further rationale
to systematically minimize glucose exposure across all PD
patients to minimize EPS risk.
There is a growing literature to suggest that UF failure in
long-term PD patients is caused by an increase in fibrosis
decreasing osmotic conductance, including evidence from
biopsies,28 computer modeling29 and peritoneal membrane
testing.30 We speculate that this fibrosis explains the changes
we have shown in patients who develop EPS, although
patients with these findings have yet to develop EPS,
suggesting that there is a difference between simple sclerosis
and EPS.21 The PCl data would support this view as,
according to the standard three-pore model, PCl should
increase with membrane size and inflammation but the lack
of effect we found might be explained by the fiber matrix/
three-pore model with fibrosis restricting protein flux across
the membrane.
There are some limitations to this study. We could not be
certain that all of the patients used as controls would not
have gone on to develop EPS as, although there was long-
term follow-up data after PD in the majority of the patients
in this group, some patients stopped PD as a result of dying
of other causes. This would tend to reduce differences
between cases and controls but despite this there were still
clear differences between the two groups. As with all studies
of EPS, it is not helped by the lack of firm diagnostic criteria
although the EPS group was carefully limited to those with
characteristic CT or operative findings (often both) with
typical clinical features and no other apparent cause. It is a
single-center study so it is not necessarily widely general-
izable, particularly with growing evidence of center differ-
ences,31 although our data were consistent with the existing
literature. There is also the possibility that cases were not
diagnosed, although this should only significantly affect the
incidence and this was similar to that found in the most
comparable population studied.2
In summary, we report in detail the longitudinal changes
in peritoneal membrane characteristics in the majority of
patients who subsequently develop EPS (not associated with
severe or prolonged peritonitis), showing that loss of UF
capacity is the predominant early change noted associated
with lower initial residual renal function and higher glucose
and icodextrin exposure. Patients with these features are at
high risk of EPS and consideration should be given to
stopping PD, while these features and a rapid PSTR at the
time of PD cessation should prompt close monitoring for
EPS after PD.
MATERIALS AND METHODS
Study design
This was a nested case–control study. We identified all patients from
the well-defined Stoke PD patient cohort with probable EPS, and
reviewed their clinical records including nursing documentation and
radiological reports. To avoid some of the uncertainty surrounding
early EPS, we selected only patients with definite EPS (surgically or
radiologically confirmed peritoneal membrane thickening and
cocooning, in conjunction with weight loss and features of bowel
obstruction). Two patients in whom EPS was associated with
persisting poorly controlled peritonitis were excluded. Each of these
patients was then matched by time on PD, and age where possible,
with four controls from the same cohort by identifying adjacent
patients from the whole database who had completed their
treatment episode on PD, neither deliberately including nor
excluding controls with UF failure. Four controls were selected to
maximize statistical power while retaining efficiency.32
Prospective collection of routine clinical measurements
Baseline demography and PD measurements for cases and controls
were retrieved from the database, along with the total number of
peritonitis episodes per patient, and comorbidity, as assessed
by the validated Stoke comorbidity index that categorizes patients
into low (score 0), intermediate (score 1–2) and high (score 42)
risk groups.
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Routine 6 monthly measurements included residual renal
function, dialysis regime and dose, and peritoneal membrane
function using the peritoneal equilibration test (solute transport
rate: D/P Cr at 4 h and net UF capacity with 2.27% glucose) was
obtained from the database. The ‘overfill’ included in the bags was
not subtracted from the 4 h UF capacity, but consistently measures
200 ml in our unit. Adequacy was expressed as weekly Kt/Vurea for
the peritoneal component, whereas the urine volume and mean
weekly urea and creatinine clearance (l per week per 1.73 m2) were
used to determine residual renal function.
Glucose exposure was calculated by summing the grams of
anhydrous glucose within the daily dialysate used for each regime
the patient had, multiplying this by the number of days they were on
that regime, and combining the results for each regime for the
annual total glucose exposure (g) of the peritoneal membrane.
Icodextrin use was recorded as a categorical value for whether it was
used at any point in the year in question.
Peritoneal protein losses were measured from the 24 h total
dialysate collection assayed by the Biuret method. A validated
correction factor33 was then used in the equation: PCl¼ 24 h
dialysate protein loss/(serum albumin/0.4783), with PCl represent-
ing the peritoneal protein clearance expressed as ml of plasma per
day. Regular dialysate protein concentrations were measured from
1999, providing data on 8 EPS cases (46 samples) and 28 controls
(107 samples) within the last 4 years of PD.
Statistical analysis
To compare the evolution of clinical measurements before the
study end point (diagnosis of EPS for cases and completion
of PD episode for controls), we aligned measurements from
the point of stopping PD backward, such that cessation of PD
counted as time 0, with 1 year before this counting as 1, and so on
until year 8. This method was used for UF capacity, solute
transport and glucose exposure, and the data are all expressed as the
yearly mean value for each group. As measurements were taken
6 monthly, this usually represents the mean of two readings per
patient.
As residual renal function declines with time on treatment, the
measurements of urine volume were aligned from starting PD
forward to year þ 8. Comparisons between EPS cases and controls
were made with all values obtained within yearly intervals, and all
values from the first 4 years of PD.
Between-group comparisons used the two-tailed unpaired t-test,
the Mann–Whitney U-test or the w2-test depending on the data type
and distribution. The paired t-test was used for longitudinal
comparisons, using all measurements between 4.5 and 5.5 years
before PD finished and comparing them with readings taken in the
last year of PD. These figures were chosen to include measurements
from as many patients as possible while maintaining a meaningful
difference in time.
The risk of developing EPS with time on treatment for the whole
PD cohort was determined from a Kaplan–Meier survival analysis of
all patients commencing PD after 1 January 1990, with the
definition of EPS for the study extended to include cases associated
with severe and prolonged peritonitis. A linear mixed model was
used to examine the PCl data as well as t-tests. These analyses were
with SPSS v17, Chicago, Illinois, USA.
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